Business Context and Reporting Period
This Form 8-K is filed by Salarius Pharmaceuticals, Inc. (not Decoy Therapeutics Inc.) on October 14, 2022. The report details a corporate action involving a reverse stock split of the Company's common stock.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure adjustments.
Material Changes
- Reverse Stock Split: The Company effected a one-for-25 reverse stock split of its issued and outstanding common stock effective October 14, 2022, at 5:00 p.m. Eastern Time.
- Share Count Adjustment: The number of issued and outstanding shares was adjusted from approximately 56.2 million to approximately 2.2 million.
- Trading Details: Beginning October 17, 2022, the stock trades on the Nasdaq Capital Market under a new CUSIP number (79400X305) on a split-adjusted basis.
- Fractional Shares: No fractional shares were issued; holders entitled to fractional shares received cash in lieu thereof based on the closing price on October 17, 2022.
- Equity Adjustments: All outstanding options, warrants, and shares reserved under equity incentive plans were adjusted proportionally.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure that the reverse split will not affect a stockholder's ownership percentage (except for fractional share cash payments). The Company noted that the split was intended to effect the change in share count and trading symbol.
Investor Verification Checklist
- Verify the new CUSIP number (79400X305) for trading purposes.
- Confirm the adjusted number of shares held in brokerage accounts post-split.
- Check for cash payments received in lieu of fractional shares.
- Review the adjusted exercise prices and share counts for any outstanding options or warrants.
- Note that the authorized share count and par value remain unchanged.